This invention is directed to compounds of Formula (I)

##STR00001## pharmaceutically acceptable salts, esters, and prodrugs thereof, to their preparation, to pharmaceutical compositions comprising compounds of Formula I, and to their uses as antimicrobial agents.

The present invention discloses an N-alkyl-N-cyanoalkylbenzamide compound of General Formula I, an intermediate of General Formula II used to prepare the compound, wherein R.sub.1 is selected from halo or C.sub.1-C.sub.3 alkyl; R.sub.2 is selected from halo or CN; R.sub.3 is selected from halo, or C.sub.1-C.sub.3haloalkyl; R.sub.4 is selected from halo; R.sub.5 is selected from H or halo; R.sub.6 is selected from C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3 haloalkyl or C.sub.1-C.sub.5 alkoxyalkyl; R.sub.7 is selected from C.sub.1-C.sub.5 alkyl; and R.sub.8 is selected from hydrogen or C.sub.1-C.sub.5alkyl. Compared with the compounds in the prior art, the compound of General Formula I has a higher activity at a low concentration. Particularly, the compound of the present invention still has 60% or higher of the insecticidal activity at a concentration below 1 ppm. This greatly reduces the amount of the compound used and the residue of the compound in farmland, and is thus environmentally friendly.

The present invention discloses an N-alkyl-N-cyanoalkylbenzamide compound of General Formula I, an intermediate of General Formula II used to prepare the compound, wherein R.sub.1 is selected from halo or C.sub.1-C.sub.3 alkyl; R.sub.2 is selected from halo or CN; R.sub.3 is selected from halo, or C.sub.1-C.sub.3haloalkyl; R.sub.4 is selected from halo; R.sub.5 is selected from H or halo; R.sub.6 is selected from C.sub.1-C.sub.3alkyl, C.sub.1-C.sub.3 haloalkyl or C.sub.1-C.sub.5 alkoxyalkyl; R.sub.7 is selected from C.sub.1-C.sub.5 alkyl; and R.sub.8 is selected from hydrogen or C.sub.1-C.sub.5alkyl. Compared with the compounds in the prior art, the compound of General Formula I has a higher activity at a low concentration. Particularly, the compound of the present invention still has 60% or higher of the insecticidal activity at a concentration below 1 ppm. This greatly reduces the amount of the compound used and the residue of the compound in farmland, and is thus environmentally friendly.

The present invention discloses a novel 3-aryl-2-propen-1-one series derivative and the synthesis processes thereof. Besides, the present invention also discloses the series derivative as a pharmaceutical composition and their use for promoting myocardial regeneration.

Disclosed are compounds of formula (I) below and pharmaceutically acceptable salts thereof, in which each of variables R.sub.1, R.sub.2, L, and Z is defined herein. Also disclosed are methods for reducing the glycemic level and treating glucagon-associated disorders with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same.

Disclosed are compounds of formula (I) below and pharmaceutically acceptable salts thereof: (I), in which each of variables R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, A.sub.1, A.sub.2, A.sub.3, A.sub.4, X and Y is defined herein. Also disclosed are methods for reducing the glycemic level and treating glucagon-associated disorders with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same.

##STR00001##

Disclosed are compounds of formula (I) below and pharmaceutically acceptable salts thereof: (I), in which each of variables R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, A.sub.1, A.sub.2, A.sub.3, A.sub.4, X and Y is defined herein. Also disclosed are methods for reducing the glycemic level and treating glucagon-associated disorders with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same.

##STR00001##

The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.

The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.

The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.

##STR00001##